By contrast, FitzGerald et al. 20 evaluated 1458 patients with prostate cancer and 1352 controls; they suggested that none of the FGFR4 polymorphism genotypes are associated with prostate cancer risk or disease aggressiveness. This evidence concerns the gene FGFR4 and Familial prostate cancer.